Objectives Anemia is observed in various malignancies including lung cancer and is recently considered to be a poor prognostic indicator. We investigated whether there is a correlation between anemia, other clinicopathologic factors, and survival.
Introduction
Anemia is commonly observed in cancer patients, although the incidence varies with the type of malignancy and the choice of treatment (1) . According to an earlier report, up to 30% of patients with malignancies suffer from anemia (2) , although the incidence of anemia varied with the clinical course of the disease and treatment such as chemotherapy (3, 4) , irradiation (5, 6) , and/or surgery (7) . The factors associated with anemia include disorders of iron metabolism (8) , reduced number of erythroid progenitor cells in the bone marrow, increased levels of inflammatory cytokines (9) , extracorpuscular hemolysis, catabolism of patients with tumor burden, and relative deficiency of erythropoietin (10) .
We previously reported that survival was significantly shorter in patients with leukocytosis or thrombocytosis compared with those without them (11, 12) . In the current study, we examined the clinical records of consecutive lung cancer patients who had anemia at the time of their first visit to our hospital and we investigated the correlation of anemia with several clinicopathological factors and survival.
Materials and Methods

Patients
This retrospective study investigated 611 patients with lung cancer who were consecutively admitted to the Okayama University Hospital between February 1976 and November 1995. The clinical features of these patients are summarized in Table 1 . There were 482 men and 129 women, with a median age of 64 years (range, 24-89 years). The histological type of lung cancer was adenocarcinoma in 239 patients, squamous cell carcinoma in 128, large cell car-cinoma in 34, and small cell carcinoma (SCLC) in 196 according to the World Health Organization (WHO) classification (13) .
Diagnosis of anemia
Anemia was defined as a hemoglobin level <13.0 g/dl in men and <12.0 g/dl in women. The pretreatment hemoglobin levels were obtained at the initial visit to our hospital before invasive diagnostic procedures were performed. Hemoglobin levels were analyzed by automated complete blood cell counting devices on ethylenediamine tetra-acetic acid (EDTA)-anti-coagulated blood. In our laboratory, the 95% confidence limit (normal range) of serum hemoglobin level is defined as 13-16 g/dl in men and 12-15 g/dl in women.
Statistical Analysis
The chi-square test or trend test was used to analyze the correlations between anemia and several categorical variables. Probabilities of survival were estimated using the Kaplan-Meier method and differences between patient groups were determined by the log-rank test. Prognostic factors were analyzed using the Cox proportional hazards model. A P level of <0.05 was considered as statistically significant. Anemia; male Hb <13 g/dl, female Hb <12 g/dl, ECOG: Eastern Cooperative Oncology Group, PS: performance status, NSCLC: non-small-cell lung cancer, SCLC: small-cell lung cancer.
Figure 1. Distribution of hemoglobin level in 401 non-small-cell lung cancer (NSCLC) patients and in 196 small-cell lung cancer (SCLC) patients.
Results
In this retrospective study of the clinical records in 611 consecutive patients with lung cancer, we identified 298 (48.8%) patients having anemia at the time of their first visit to our hospital. Frequency of anemia was 50.0% (241/482) in men and 44.2% (57/129) in women. As shown in Fig. 1 , no significant differences of serum hemoglobin level between patients with non-small cell lung cancer (NSCLC) and those with SCLC were observed.
The relation between anemia and clinicopathologic factors is shown in Table 2 . There was a significant correlation between anemia and age (p<0.0001), or ECOG performance status (PS) (p=0.0002). Whereas anemia did not significantly correlate with gender, histological type, clinical stage, and serum level of lactate dehydrogenase (LDH).
As shown in Fig. 2A , survival was significantly shorter in 298 patients with anemia (median survival time (MST): 7.5 months) compared to 313 patients without it (MST: 11.8 months, p<0.0001). Furthermore, when analyzing NSCLC ( Fig. 2B) and SCLC (Fig. 2C ) separately, the survival was also significantly shorter in patients with anemia compared to those without it both in NSCLC (MST: 6.5 months vs. 10.5 months, p=0.0002) and in SCLC (MST: 9.2 months vs. 14.4 months, p=0.01111). The severity of anemia significantly correlated survival in all lung cancer patients (p< 0.001) and NSCLC patients (p<0.001) ( n: number of patients, MST: median survival time, Severe: <11 g/dl in men or <10 g/dl in women; Moderate: 11-12 g/dl in men or 10-11 g/dl in women; Mild: 12-13 g/dl in men or 11-12 g/dl in women; Normal: >13 g/dl in men or >12 g/dl in women. (p=0.0002), clinical stage (p<0.0001), ECOG PS (p< 0.0001), histological type (SCLC vs. NSCLC) (p=0.0027), serum level of LDH (p=0.0029), and sex (p=0.0001) appeared to have independent prognostic significance. Age appeared to have no significant effect on survival (Table 4 ).
Figure 2. Relationship between hemoglobin level and overall survival in all lung cancer patients (A), NSCLC patients (B), and SCLC patients (C; Kaplan-Meier analysis). Hemoglobin level was measured at the first visit of all these patients (611 cases). Patients whose hemoglobin levels were lower than 13 g/dl in men and 12 g/dl in women were diagnosed as having anemia. Survival of all lung cancer patients is significantly shorter in patients with anemia (bold line, median survival
Discussion
The prevalence of anemia in patients with gynecological cancer, lung cancer, colon cancer, and breast cancer was reported to be 26%-85%, 8%-84%, 30%-67%, and 41%-82%, respectively (2) , which was comparable with the results of the present study. Our results also suggest that anemia is more common in elderly patients and patient with poor PS.
In addition, we demonstrated that anemia at the first presentation of lung cancer is an independent prognostic factor by multivariate analysis of prognostic factors using the Cox proportional hazards model. It has been already reported that anemia was associated with shorter survival in patients with several types of cancer including gynecological cancer, renal cell cancer, gastric cancer, and lung cancer (1). Thus, our data are in accordance with the results of the previous reports in patients with various tumors.
The reasons for the poor prognosis of lung cancer patients with anemia have not been clarified yet. Tumor cells are known to secrete soluble molecules such as interleukin-1 (IL-1), interferon gamma, and tumor necrosis factor (TNF), which may develop anemia in cancer patients by hemolysis, suppression of erythropoiesis, and impairment of erythropoietin response on erythroid progenitor cells. Accordingly, anemia may be regarded as a paraneoplastic phenomenon. Thus patients with anemia might have biologically more aggressive tumor cell clones compared to patients without anemia.
As a further explanation of why lung cancer patients with anemia have poor prognosis, radiation (14) and chemotherapy (15) might be more effective under well-oxygenated conditions than under hypoxic conditions as reported previously in the patients with various cancers (16) . It has also been reported that hypoxic condition was associated with substantial drug resistance in brain tumor cell lines (15) .
In conclusion, we demonstrated that anemia was frequently observed in patients with lung cancer at the first visit in the hospital and survival was significantly shorter in pa-tients with anemia compared with patients without it. Furthermore, we showed that survival of lung cancer patients was independently influenced by pretreatment serum hemoglobin levels using multivariate analysis. These results suggest that anemia determined at the time of first presentation is a useful indicator of the prognosis in patients with lung cancer.
